EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG announces key results of its Phase II trial of AX200 for the treatment of Acute Ischemic Stroke

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
Research & Development


Ad-hoc release

SYGNIS Pharma AG announces key results of its Phase II trial of AX200 for the
treatment of Acute Ischemic Stroke

Heidelberg,  15  December  2011  -  SYGNIS  Pharma  AG  (Frankfurt:  LIOK;  ISIN
DE000A1E9B74; Prime Standard) today  announces  key  results  of  the  Phase  II
clinical trial (AXIS 2) of  AX200  to  treat  acute  ischemic  stroke.  The  key
results on the relevant  primary  endpoint,  using  the  modified  Rankin  Scale
(mRS), and secondary endpoint, using the National Institutes  of  Health  Stroke
Scale (NIHSS), show no improvement in patient outcome relative to  the  placebo-
treated patient. As a result, the study missed its endpoints.

The primary endpoint of significant  functional  improvement  according  to  mRS
evaluated AX200 treated  patients  relative  to  placebo-treated  patients.  The
study recorded no clinical  improvement  and  did  not  show  any  statistically
significant difference. The secondary endpoint of improvement  using  the  NIHSS
relative to placebo-treated patients did also not record a  clinically  relevant
or statistically significant difference.  The  randomized,  double-blind  AXIS 2
trial enrolled 328 patients in 78 centers throughout Europe.

SYGNIS Pharma will continue to analyse the current data set  and  the  new  data
that will become available in the weeks ahead. Full data  will  be  available in
Q1 2012.

For further information please contact:

|Dr. Franz-Werner Haas                   |
|Senior VP  Operations                   |
|Tel: +49 (0) 6221-454 812               |
|Email:   |

### Disclaimer
This publication is intended for information only  and  constitutes  neither  an
offer to sell nor an invitation to buy securities. Some statements  included  in
this press release, relating neither  to  proven  financial  results  nor  other
historical data, should be viewed as forward-looking, i.e.  not  definite.  Such
statements are mainly predictions of future results,  trends,  plans  or  goals.
These statements should not be considered to be  total  guarantees  since  given

their  very  nature  they  are  subject  to  known   and   unknown   risks   and
imponderability and can be affected by other factors as a consequence  of  which
the actual results, plans and goals of SYGNIS  Pharma  AG  may  deviate  greatly
from the established  conclusions  or  implied  predictions  contained  in  such
statements. SYGNIS does  not  undertake  to  publicly  update  or  revise  these
statements in the light of new information or future results or  for  any  other

Further inquiry note:
|Dr. Franz-Werner Haas                   |
Senior VP  Operations                   
Tel: +49 (0) 6221-454 812               

end of announcement                               euro adhoc 

issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Stuttgart, Düsseldorf, Hannover, München 
language:   English

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: